CARI provided content experts to the Advisory Group that worked on developing the Kidney Disease guideline. Other members included representatives from the Australian Diabetes Society, the Australian Diabetes Association Education group, the Dietitians Association of

Australia, researchers, a consumer and medical advisor. While it can be a challenge to work according to different criteria and policies, and to coordinate a large group of contributors, it is satisfying and rewarding to have other groups invite CARI to contribute to guidelines they are developing that are relevant to the care of patients with kidney disease. It is important for nephrologists to have an input into guidelines that relate to those with CKD and it is also beneficial to have a CARI version Ibrutinib clinical trial of these guidelines, to help ensure that these documents are disseminated to all the relevant interest groups. The National Health and Medical Research Council (NH & MRC) gave their formal approval of the Type 2 Diabetes: Kidney Disease guideline on 12

June 2009 and thanked Prof Stephen Colagiuri, Prof Jonathan Craig, Assoc Prof Steve Chadban and all the members of the Expert Advisory Group for their contribution in bringing the guideline to completion. This supplement also contains guidelines on ‘Acceptance onto Dialysis’ (an update of previous guidelines published in March 2000), ‘Living Kidney Donor’ and ‘Renovascular Disease’. The latter two topics have not previously been published by CARI. A further important development for CARI has been Deforolimus datasheet the selection of some 16 sets of CARI Guidelines for inclusion on the NH & MRC – National Institute of Clinical Studies (NICS) ‘Australian Clinical Practice Guidelines

Portal’ and ‘Guidelines in Development Register’ (accessible via http://www.clinicalguidelines.gov.au). The CPG Portal has been developed so that there is a single online entry point for evidence-based Australian guidelines. Guidelines have to meet certain strict selection criteria before they are accepted for inclusion on the Portal. On behalf of the CARI Steering BCKDHB Committee, and all in the nephrology community associated with CARI, I would like to sincerely thank the members of all of these groups who have laboured over these guidelines on a voluntary basis and spent many hours reading and appraising innumerable articles in their own time. I think this is an opportunity to thank all the organizations that have provided support for CARI. The major sponsors in the pharmaceutical industry; Amgen Australia, Janssen-Cilag Pty Ltd and Roche Products Pty Ltd have provided very generous support of CARI and its various endeavours over a considerable number of years now. We are grateful to these organizations for this continued untethered support of CARI education, guideline development and implementation projects over the years.